Gland Pharma
Gland Pharma Limited, commonly referred to as Gland Pharma, is a prominent player in the pharmaceutical industry, headquartered in Hyderabad, India. Established in 1978, the company has made significant strides in the development and manufacturing of high-quality injectable pharmaceuticals, particularly in the areas of oncology, anaesthesia, and critical care. With a strong presence in both domestic and international markets, Gland Pharma has earned a reputation for its robust product portfolio, which includes a range of generic injectables and complex formulations. The company is recognised for its commitment to quality and innovation, having achieved several key milestones, including successful partnerships with global healthcare providers. Gland Pharma's dedication to excellence positions it as a leader in the injectable segment, contributing to improved patient outcomes worldwide.
DitchCarbon Score
How does Gland Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Gland Pharma's score of 0 is lower than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Gland Pharma's reported carbon emissions
In 2023, Gland Pharma reported total carbon emissions of approximately 11929600 kg CO2e from Scope 1 and 80669600 kg CO2e from Scope 2. This reflects a slight decrease in Scope 1 emissions compared to 2022, where emissions were about 12579300 kg CO2e, while Scope 2 emissions increased from approximately 78475200 kg CO2e in the previous year. For 2024, Gland Pharma anticipates an increase in emissions, with projected Scope 1 emissions at about 15736000 kg CO2e and Scope 2 emissions at approximately 81154000 kg CO2e. Despite these figures, Gland Pharma has not disclosed any specific reduction targets or initiatives as part of their climate commitments. The absence of defined reduction strategies suggests a need for further development in their sustainability efforts. Overall, Gland Pharma's emissions data highlights the ongoing challenges in managing carbon footprints within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 12,579,300 | 00,000,000 | 00,000,000 |
| Scope 2 | 78,475,200 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Gland Pharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
